{"id":7110,"date":"2022-03-14T16:06:00","date_gmt":"2022-03-14T16:06:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3690928_HK90928_0"},"modified":"2022-03-14T16:06:00","modified_gmt":"2022-03-14T16:06:00","slug":"sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=7110","title":{"rendered":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress"},"content":{"rendered":"<div id=\"dvContent\" readability=\"104.68551316985\">\n<p><i>Sirnaomics CTO <span class=\"xn-person\">Dmitry Samarsky<\/span>, PhD, to Also Present OPT Congress Opening Remarks<\/i><\/p>\n<p><span class=\"xn-location\">GAITHERSBURG, Md.<\/span> and SUZHOU, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">March 15, 2022<\/span> \/PRNewwire\/&nbsp;&#8212; Sirnaomics Ltd. (&#8220;<b>Sirnaomics<\/b>&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and product pipeline at the Oligonucleotide &amp; Precision Therapeutics (OPT) Congress. The OPT Congress is taking place on March 15\u201316, 2022 in <span class=\"xn-location\">Boston<\/span>.<\/p>\n<p>Sirnaomics&#8217; proprietary GalNAc-conjugate delivery platforms rely on peptide conjugates and\/or unique RNA structures that allow knockdown of single or multiple distinct mRNA targets. The Company&#8217;s GalAhead\u2122 delivery platform conjugates GalNAc moieties to unique RNAi trigger structures that can target one (mxRNA\u2122) or more (muRNA\u2122) genes simultaneously. Dr. <span class=\"xn-person\">Dmitry Samarsky<\/span>, Sirnaomics Chief Technology Officer, will present data demonstrating mxRNA efficacy in primary hepatocytes (in vitro) and in mice (in vivo). He will also present results of a 33-week study in non-human primates conducted with the candidate molecule for Sirnaomics&#8217; frontrunner GalAhead\u2122 therapeutic program STP122G, targeting coagulation Factor XI, and report on progress made with other therapeutic programs based on the GalAhead\u2122 platform.<\/p>\n<p><b>Presentation Details<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Presentation Title:<\/b>&nbsp;mxRNA\u2122: Miniaturized RNAi Triggers Composed of Single Oligonucleotides<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b>Presentation Segment:<\/b>&nbsp;Advances in Targeted Delivery<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b>Presenter: <\/b><span class=\"xn-person\">Dmitry Samarsky<\/span>, PhD, Sirnaomics Chief Technology Officer<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b>Time\/Date:<\/b>&nbsp;10:30 a.m. ET, <span class=\"xn-chron\">Tuesday, March 15, 2022<\/span>. The presentation will be available on-demand via the OPT Congress website after the event.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b>Location: <\/b>Revere Hotel Boston Common<\/li>\n<\/ul>\n<p>Dr. Patrick Lu, founder, chairman of the Board, Executive Director, President and CEO of Sirnaomics, stated, &#8220;The advancement of our proprietary GalAhead\u2122 technology and expansions of the GalNAc program is indicative of Sirnaomics&#8217; solid technology platforms and continuing growth of our drug pipeline. By adding GalNAc targeting delivery with our polypeptide-based delivery technology, we are seeking to address unmet clinical needs in oncology, fibrosis and liver-related diseases.&#8221;<\/p>\n<p>Dr. Samarsky said, &#8220;We are highly satisfied with the outstanding performance of our proprietary GalAhead\u2122 technology platform, in particular the mxRNA\u2122, or miniaturized single-oligo RNAi triggers, which yield strong and durable knockdown of targeted genes. After successful validation of the technology, we have moved quickly into developing the therapeutic programs based upon it. For this we have established a reproducible process, which allows us to quickly generate the candidate molecules for the IND-enabling studies. We are planning to file our first GalAhead\u2122 IND later this year, followed by several more in 2023.&#8221;<\/p>\n<p>On behalf of request from the Cambridge Healthtech Institute, organizer of the Symposium, Dr. Samarsky will also chair the first half-day session of the event.<\/p>\n<p>For more information about Sirnaomics&#8217; presentation, visit the event website at <a target=\"_blank\" href=\"https:\/\/www.optcongress.com\/oligonucleotide\" rel=\"nofollow noopener\">https:\/\/www.optcongress.com\/oligonucleotide<\/a>.<\/p>\n<p><b>About Sirnaomics<br \/><\/b>Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">the United States<\/span>, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at <a target=\"_blank\" href=\"http:\/\/www.sirnaomics.com\/\" rel=\"nofollow noopener\">www.sirnaomics.com<\/a>.<\/p>\n<p><b>Contact:<br \/><\/b><span class=\"xn-person\">Dmitry Samarsky<\/span>, PhD <br \/>Chief Technology Officer, Sirnaomics Ltd. <br \/>Email: <a target=\"_blank\" href=\"mailto:DmitrySamarsky@sirnaomics.com\" rel=\"nofollow noopener\">DmitrySamarsky@sirnaomics.com<\/a><\/p>\n<p><b>Investor Relations:<\/b>&nbsp;<br \/><span class=\"xn-person\">Nigel Yip<\/span><br \/>Chief Financial Officer, <span class=\"xn-location\">China<\/span>, Sirnaomics Ltd. <br \/>Email: <a target=\"_blank\" href=\"mailto:NigelYip@sirnaomics.com\" rel=\"nofollow noopener\">NigelYip@sirnaomics.com<\/a> <\/p>\n<p><b>US Media Contact:<\/b>&nbsp;<br \/><span class=\"xn-person\">Alexis Feinberg<\/span> <br \/>Tel: +1 203 939 2225 <br \/>Email: <a target=\"_blank\" href=\"mailto:Alexis.Feinberg@westwicke.com\" rel=\"nofollow noopener\">Alexis.Feinberg@westwicke.com<\/a><\/p>\n<p><b>Asia Media Contact:<\/b>&nbsp;<br \/><span class=\"xn-person\">Bunny Lee<\/span> <br \/>Tel: +852 3150 6707 <br \/>Email: <a target=\"_blank\" href=\"mailto:sirnaomics.hk@pordahavas.com\" rel=\"nofollow noopener\">sirnaomics.hk@pordahavas.com<\/a><\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK90928&amp;sd=2022-03-14\"> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide--precision-therapeutics-congress-301501988.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide&#8211;precision-therapeutics-congress-301501988.html<\/a><\/p>\n<\/p><\/div>\n<p>Source: Sirnaomics Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 15, 2022 \/PRNewwire\/&nbsp;&#8212; Sirnaomics Ltd. (&#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and product pipeline at [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":7111,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-7110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=7110\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog\" \/>\n<meta property=\"og:description\" content=\"Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 15, 2022 \/PRNewwire\/&nbsp;&#8212; Sirnaomics Ltd. (&#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and product pipeline at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=7110\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-14T16:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress\",\"datePublished\":\"2022-03-14T16:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110\"},\"wordCount\":610,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110\",\"name\":\"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png\",\"datePublished\":\"2022-03-14T16:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7110#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=7110","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog","og_description":"Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 15, 2022 \/PRNewwire\/&nbsp;&#8212; Sirnaomics Ltd. (&#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and product pipeline at [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=7110","og_site_name":"My Blog","article_published_time":"2022-03-14T16:06:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=7110#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress","datePublished":"2022-03-14T16:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110"},"wordCount":610,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=7110","url":"https:\/\/transmediavictoria.net.au\/?p=7110","name":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png","datePublished":"2022-03-14T16:06:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7110#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=7110"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=7110#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/sirnaomics-to-present-latest-developments-on-its-galnac-based-liver-targeting-platforms-and-product-pipeline-at-the-2022-oligonucleotide-precision-therapeutics-congress.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=7110#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide &amp; Precision Therapeutics Congress"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/7110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7110"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/7110\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/7111"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}